Appendix 4E and 2026 Annual Report

Summary by 6ix AI

The report indicates a substantial increase in net loss after tax compared to the previous year, attributed mainly to rising operating expenses and decreased income. Additionally, the company has transitioned to a dual-track business model, combining AI-driven drug discovery with pharmaceutical commercialization, and has executed several licensing agreements with international partners. No dividends were declared during the reporting period, and the financial statements have been audited with an unmodified opinion issued.

Written by 6ix AI from the company’s filing. How 6ix writes summaries